[go: up one dir, main page]

MX2019000677A - Células miméticas de células b. - Google Patents

Células miméticas de células b.

Info

Publication number
MX2019000677A
MX2019000677A MX2019000677A MX2019000677A MX2019000677A MX 2019000677 A MX2019000677 A MX 2019000677A MX 2019000677 A MX2019000677 A MX 2019000677A MX 2019000677 A MX2019000677 A MX 2019000677A MX 2019000677 A MX2019000677 A MX 2019000677A
Authority
MX
Mexico
Prior art keywords
cell
mimetic
cells
mimetic cells
methods
Prior art date
Application number
MX2019000677A
Other languages
English (en)
Inventor
Fussenegger Martin
Xie Mingqi
Original Assignee
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59564137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019000677(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP16180000.8A external-priority patent/EP3272877A1/en
Application filed by Eth Zuerich filed Critical Eth Zuerich
Publication of MX2019000677A publication Critical patent/MX2019000677A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a células miméticas de células ß. Además, se proporcionan métodos para producir células miméticas de células ß así como métodos de uso de las células miméticas de células ß como un medicamento y métodos de uso de las células miméticas de células ß para la prevención, el retraso de la progresión o el tratamiento de una enfermedad metabólica en un sujeto.
MX2019000677A 2016-07-18 2017-07-17 Células miméticas de células b. MX2019000677A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16180000.8A EP3272877A1 (en) 2016-07-18 2016-07-18 B-cell-mimetic cells
EP16200258 2016-11-23
PCT/EP2017/067981 WO2018015330A1 (en) 2016-07-18 2017-07-17 B-cell-mimetic cells

Publications (1)

Publication Number Publication Date
MX2019000677A true MX2019000677A (es) 2019-06-10

Family

ID=59564137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000677A MX2019000677A (es) 2016-07-18 2017-07-17 Células miméticas de células b.

Country Status (13)

Country Link
US (1) US20190282710A1 (es)
EP (1) EP3485040B1 (es)
JP (1) JP2019520837A (es)
KR (1) KR20190026786A (es)
CN (1) CN109563487A (es)
AU (1) AU2017300590A1 (es)
BR (1) BR112019000837A2 (es)
CA (1) CA3030642A1 (es)
IL (1) IL264169A (es)
MX (1) MX2019000677A (es)
SG (1) SG11201811763SA (es)
WO (1) WO2018015330A1 (es)
ZA (1) ZA201900891B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12286645B2 (en) 2020-01-28 2025-04-29 Hamad Bin Khalifa University Generation of induced pluripotent stem cells (IPSCs) with GLUT2 mutation or FOXA2 deletion, methods of preparing same, and methods of using same
US20240342340A1 (en) * 2020-12-28 2024-10-17 Mochida Pharmaceutical Co., Ltd. Multilayer structure using chemically crosslinked alginic acid
EP4268857A4 (en) * 2020-12-28 2025-09-24 Mochida Pharm Co Ltd NEW CROSSLINKED ALGINATE GEL FIBER COATED WITH A MULTI-LAYER POLYMER
CN116710110A (zh) 2020-12-28 2023-09-05 持田制药株式会社 新型的多层聚合物涂层交联海藻酸凝胶纤维
CN115147371B (zh) * 2022-06-30 2025-04-11 昆明澳滇科技有限公司 一种双输入四室模型用于动态pet/ct影像肝细胞癌的评估方法
WO2024106171A1 (ja) * 2022-11-18 2024-05-23 セルプロジャパン株式会社 細胞培養方法および培養上清の製造方法
WO2025064980A1 (en) * 2023-09-21 2025-03-27 Northwestern University Engineered cells producing oncotherapeutics and applications thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
EP0585368B1 (en) 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
AU7568094A (en) 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
GB9502830D0 (en) * 1995-02-14 1995-04-05 Ecole Polytech Regulation of polypeptide production in cells
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
WO2000004171A1 (en) * 1998-07-15 2000-01-27 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
EP2298357A1 (en) * 2000-03-13 2011-03-23 Engene, Inc. Compositions and methods for regulated protein expression in gut
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
US7790690B2 (en) * 2000-10-11 2010-09-07 U.S. Department Of Veterans Affairs Glucose sensitive regulator of insulin transcription
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
JP4294497B2 (ja) * 2002-04-16 2009-07-15 協和発酵キリン株式会社 内分泌系細胞株とその利用法
JP3828561B2 (ja) * 2002-10-02 2006-10-04 直哉 小林 グルコース感受性により改変されたインスリンを分泌する不死化肝細胞株
ATE517119T1 (de) 2003-12-03 2011-08-15 Novo Nordisk As Einzelketteninsulin
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
EP1890708A4 (en) * 2005-06-01 2009-07-15 Biotec Inst For Internat GLUCOSE INDUCIBLE INSULIN EXPRESSION AND METHODS OF TREATING DIABETES
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
EP1996223A1 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
EP1996709A2 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
NZ588857A (en) 2008-04-22 2012-07-27 Univ Case Western Reserve Isoform-specific insulin analogue for control blood sugar levels
EP2376099A4 (en) 2008-12-19 2012-04-25 Univ Indiana Res & Tech Corp INSULIN AGAIN YL-BASED GROWTH FACTORS WITH HIGH ACTIVITY AT THE INSULIN RECEPTOR
JP5755566B2 (ja) 2008-12-19 2015-07-29 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
EP2616539A1 (en) * 2010-09-15 2013-07-24 Ramot at Tel-Aviv University Ltd. Methods of expanding and redifferentiating islet beta cells
KR20130097789A (ko) * 2010-10-15 2013-09-03 코넬 유니버시티 내분비, 위장관 또는 자가면역 장애 치료를 위한 조성물 및 방법
JP6841761B2 (ja) * 2014-09-22 2021-03-10 ザ ロックフェラー ユニバーシティー 細胞活性を調節するための組成物および方法

Also Published As

Publication number Publication date
JP2019520837A (ja) 2019-07-25
AU2017300590A1 (en) 2019-01-24
WO2018015330A1 (en) 2018-01-25
ZA201900891B (en) 2019-12-18
EP3485040B1 (en) 2021-04-14
CN109563487A (zh) 2019-04-02
SG11201811763SA (en) 2019-02-27
IL264169A (en) 2019-02-28
CA3030642A1 (en) 2018-01-25
US20190282710A1 (en) 2019-09-19
EP3485040A1 (en) 2019-05-22
KR20190026786A (ko) 2019-03-13
BR112019000837A2 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
MX2022001105A (es) Anticuerpos anti tigit.
MX2022007522A (es) Anticuerpos anti-cd27.
MX2019000677A (es) Células miméticas de células b.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
WO2017030823A3 (en) Anti-tigit antibodies
MD20170020A2 (ro) Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
MY179105A (en) Methods of treating alzheimer's disease
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
WO2015159155A3 (en) Novel ademetionine formulations
PH12017500120A1 (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
WO2015160470A3 (en) Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease
PH12017501979A1 (en) Pharmaceutical compound
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
MA40574A (fr) Traitement de maladies fibrotiques
IN2013MU03855A (es)
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci